Quantitation of a novel antiemetic (ADR-851) in plasma and urine by reversed-phase high-performance liquid chromatography with fluorescence detection

A sensitive and specific bioanalytical method for quantitation of a novel antiemetic (ADR-851) in plasma and urine has been developed and validated. The drug and internal standard (metoclopramide) are extracted from the plasma matrix by solid-phase extraction on cyanopropyl bonded-phase columns. After extraction, samples are separated by isocratic reversed-phase high-performance liquid chromatography. The parent drug, internal standard and a yet unidentified metabolite are detected by fluorescence. The method requires 1.0 ml of plasma or 0.1 ml of urine and has a lower limit of quantitation of 2 ng/ml with 10.9% relative standard deviation (R.S.D.). Method linearity has been established over a 2-800 ng/ml range when 1.0 ml of plasma is used. The intra- and inter-day imprecisions for the method are typically better than 6% and 11% R.S.D., respectively, in both plasma and urine over the entire dynamic range. The pooled estimate of bias is less than 5% and attests to the excellent accuracy.     

Determination of busulfan in human plasma by gas chromatography with electron-capture detection

A simple and highly sensitive gas chromatographic method has been developed for the determination of busulfan in human plasma. After extraction of plasma specimens (clinical or spiked) with ethyl acetate, busulfan and the internal standard [1,8-bis(methanesulfonyloxy)octane] were derivatized with 2,3,5,6-tetrafluorothiophenol to yield compounds monitored by a 63Ni electron-capture detector. Sample recoveries from extraction and derivatization were greater than 78 and 91%, respectively. The limit of quantitation was 0.01 microgram/ml (0.04 microM) in 1 ml of plasma with a linear relationship over the 0.01-1.0 micrograms/ml (0.04-4 microM) concentration range. The method has been applied to analyze the plasma versus time profile of busulfan in human subjects following administration of an oral dose of 4 mg/kg per day as a marrow ablative chemotherapy for bone marrow transplantation.     

Determination of a new calcium antagonist and its main metabolite in plasma by thermospray liquid chromatography-mass spectrometry.

A highly sensitive thermospray liquid chromatographic-mass spectrometric method has been developed for the simultaneous determination of FRC-8653 (I), a new calcium antagonist, and its main metabolite (M-4) in plasma. A deuterated analogue of I was added to the plasma as the internal standard. After the purification and concentration of the plasma sample on bonded-phase disposable columns, the extract was injected into the thermospray liquid chromatograph and analysed by selected-ion monitoring mass spectrometry. The calibration curves obtained were linear over the concentration range 0.5-100 ng/ml. The limits of quantification are 0.5 ng/ml for I and 1 ng/ml for M-4 in plasma, which are sufficient to evaluate plasma concentrations after oral administration to rats.     

Liquid chromatographic determination of sotalol in plasma and urine employing solid-phase extraction and fluorescence detection

A liquid chromatographic method using a solid-phase extraction procedure for the quantification of sotalol in plasma and urine is described. Sotalol is eluted from an extraction column with ethyl acetate-acetonitrile (1:2) and, after separation by reversed-phase high-performance liquid chromatography on a mu Bondapak C18 column, is quantified by fluorescence detection at excitation and emission wavelengths of 240 and 310 nm, respectively. The method has been demonstrated to be linear over the concentration ranges 10-6000 ng/ml in plasma and 0.5-100 micrograms/ml in urine. Mean inter-assay accuracy of the method for plasma ranged from 93 to 100% and for urine from 102 to 114%; precision ranged from 0.5 to 1.6% for plasma over a concentration range of 200-4000 ng/ml and for urine from 0.7 to 2.0% at concentrations of 2-50 micrograms/ml. Mass spectrometry confirmed the presence of sotalol in isolated chromatographic fractions of plasma and urine extracts from subjects given sotalol orally.     

Quantitation of N,N,N',N'-tetrakis (2-hydroxypropyl)-ethylenediamine in plasma by gas chromatography

A wide-bore capillary gas chromatographic method with nitrogen-selective thermionic detection is described for the quantitative analysis of N,N,N',N'-tetrakis (2-hydroxypropyl)ethylenediamine (Quadrol) in plasma. N,N,N',N'-tetrakis (2-hydroxybutyl)ethylenediamine is used as an internal standard. Rat or human plasma samples (0.5 ml) are mixed with internal standard, adjusted to alkaline pH and subjected to a single extraction with dichloromethane. Quadrol recovery from plasma typically exceeds 90%. The method is linear over the range 1.0-50 micrograms/ml. The working detection limit is 0.5 microgram/ml and the analysis time is under 7 min. The procedure has been used to obtain plasma concentration versus time data for the evaluation of Quadrol pharmacokinetics in rats.     

The Determination of a New Trifluorinated Quinolone,Fleroxacin, Its N-Demethyl,and N-Oxide Metabolites in Plasma and Urine by High Performance Liquid Chromatography with Fluorescence Detection

Abstract

A liquid chromatographic method is described for the determination of the new fluoroquinolone Ro 23–6240 and its N-demethyl and N-oxide metabolites in plasma and urine. The three substances were extracted from aqueous solution with dichloromethane/isopropanol containing sodium dodecyl sulphate. After evaporation and reconstitution, samples were analysed on a reversed-phase column using ion pair chromatography and fluorescence detection. The limit of quantification was 10–20 ng/ml (RSD 4%) using a 0.5 ml plasma sample, and the inter assay precision was 3–10% over the concentration range 50 ng/ml to 20 μg/ml. Recovery from plasma was 81% (RSD 10%) over the range 10 ng/ml to 5 μg/ml. The method has been applied successfully to the analysis of several thousand samples from human pharmacokinetic studies. Care has to be taken to avoid exposure of samples to direct sunlight, and the use of opaque vessels for sample storage and handling is recommended.     

Rapid Determination of Bupropion in Human Plasma by High Performance Liquid Chromatography

Abstract

A high performance liquid chromatographic (HPLC) technique has been developed for the determination of bupropion hydrocloride (Bup) in human plasma, using a reversed-phase method, with UV detection at 250 nm.

The internal standard 5-(P-methylphenyl)-5-phenylhydantoin (MPPH), was used as an aid to quantitation. The plasma was deprotemized with acetonitrile and the clear supernatant was directly injected in the chromatographic system. The lower limit of quantitation was 5.0 ng/ml using only 100 μl of plasma sample.

Linear regression analysis for the calibration plots obtained on five different days over a two-week period for the the two ranges used (10–250 ng/ml and 250–2000 ng/ml) in plasma indicated excellent linearity and reproducibility. The mean recovery of spiked Bup in plasma samples over the concentrations studied was found 96.5 ± 3.14%.

The method revealed that more than 30% of Bup was lost when the supernatant was stored at room temperature for 24 hrs.     

Measurement of Nicotine in Plasma by High-Performance Liquid Chromatography

Abstract

A new procedure has been developed to measure nicotine in blood plasma by high-performance liquid chromatography (HPLC). Nicotine is extracted from plasma by elution with cholorform. Final determination is achieved by isocratic HPLC with ultraviolet detection. Twenty microliters of plasma extract is deluted over a silica column at a flow rate of 1.0 ml/min with a dioxane:isopropanol:NH₄OH (80:3.0:0.4) mobile phase. The procedure is sensitive to 0.05 ug of nicotine per ml of plasma and is linear within the range of 0.05 to 10.0 ug/ml of plasma. When a known amount of nicotine was added to plasma, the concentration of nicotine measured averaged 99.9 + 3.9 (S.D.)% of the known concentration. The within-sample coefficient of variation was 3.9%     

High-performance liquid chromatographic assay for the alpha-melanotropin[4,10] fragment analogue (Melanotan-II) in rat plasma.

A high-performance liquid chromatographic (HPLC) procedure has been developed for the quantification of Melanotan-II (MT-II), a cyclic heptapeptide which promotes rapid tanning of the skin, in rat plasma. The method involves precipitation of plasma proteins followed by direct-injection HPLC with ultraviolet detection. Calibration curves were linear over the range 100-1000 ng/ml for rat plasma. The method is reproducible and reliable with a detection limit of 50 ng/ml in plasma. Within- and between-day precision and accuracy reported as coefficient of variation and relative error, respectively, were < 7%. The application of the assay was successfully demonstrated by quantifying the concentration of MT-II in rat plasma samples following an intravenous dose of 0.3 mg/kg.     

Determination of (E)-2,3-dichloro-4-methoxyphenyl)-2-furanylmethanone-O-[2-(diethylamino) ethyl]oxime methanesulphonate (ANP-4364) in plasma using gas chromatography with electron-capture detection

A gas chromatographic method has been developed that permits the accurate and specific determination of the antianginal agent ANP-4364 in plasma. ANP-4364 is extracted with n-hexane containing ethyl chloroformate and, after a clean-up procedure, derivatized to the trichloroethyl carbamate, which is assayed on a gas chromatograph equipped with an electron-capture detector. Accurate determinations are possible over a concentration range from 1 to 50 ng/ml of ANP-4364 in plasma with a relative standard deviation of 7.5%. The minimum detectable concentration is 0.5 ng/ml. Plasma levels of ANP-4364 in dogs receiving oral (10 mg/kg) or intravenous (0.1 mg/kg) dosing have been determined.     

Electroanalytical determination of vinca alkaloids used in cancer chemotherapy

A differential pulse polarographic method has been developed for determination of the antineoplastic agents vincristine and vinblastine at ng ml level, in biological fluids such as plasma and urine. The vincristine and vinblastine are extracted from urine with Amberlite XAD-2. Linear calibration plots are obtained for both over the concentration range 0.005-5 mug ml . The relative standard deviations found were 1.7% for analysis of the pure drugs, 7.3% for urine and 8.6% for plasma.     

A Rapid and Sensitive Method for The Determination of Diclofenac Sodium in Plasma By High-Performance Liquid Chromatography

Abstract

A rapid and sensitive high-performance liquid chromatographic method for the determination of diclofenac sodium in plasma has been developed. The method is specific and free of interference from metabolites and common anti-inflammatory agents. The UV detector (215 nm) response was linear over a range of 5-1000 ng/ml. Day-to-day and within-day calibration curves were reproducible. The method was validated by analysis of spiked human plasma samples, partly in a blind fashion. The accuracy and precision of the method are satisfactory over the range of 5-1000 ng/ml. The method was cross-checked with the GC method. Results show a correlation coefficient of 0.983 and a slope of 1.04. The method is suitable for the routine analysis of large numbers of plasma samples usually obtained in bioavailability and pharmacokinetic studies.     

Determination of captopril and its mixed disulphides in plasma and urine by high-performance liquid chromatography

A high-performance liquid chromatographic method has been developed which enables sensitive determination of captopril and its mixed disulphides in plasma and urine after oral administration of a new antihypertensive agent, 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (DU-1219, I). Captopril is derivatized with a new reagent, N-(4-benzoylphenyl)maleimide and the derivative is extracted with chloroform and assayed using a liquid chromatograph equipped with an ultraviolet detector at 254 nm. Mixed disulphides of captopril with thiol compounds such as cysteine, glutathione and plasma proteins are reduced with tributylphosphine to form captopril, followed by derivatization with N-(4-benzoylphenyl)maleimide. Accurate determinations are possible over a concentration range of 10-500 ng/ml captopril in plasma, and 100-2500 ng/ml captopril in urine. The coefficients of variation of captopril in plasma (200 ng/ml) and urine (500 ng/ml) are 3.7% and 2.6%, respectively, and those of mixed disulphides of captopril are similar to those of captopril. Plasma levels and urinary excretion of captopril and its mixed disulphides in healthy volunteers following single oral administration of I (50 mg) have also been determined.     

A novel approach to the rapid determination of amoxicillin in human plasma by solid phase microextraction and liquid chromatography

A new approach to the rapid determination of amoxicillin (AMO) in human plasma followed by solid phase microextraction (SPME) fiber coatings based on conducting polymers (polypyrrole and polythiophene) and high performance liquid chromatography (HPLC) has been described. The porous structures of the electrochemically deposited polymer coatings have been characterized by scanning electron microscopy (SEM). The experimental parameters relating to the extraction efficiency of the SPME fibers such as pH, extraction time and desorption conditions (solvents, time) were studied and selected. The SPME/HPLC-UV method was linear over a working range of 1-50 μg ml(-1). The inter-day accuracy (expressed as coefficients of variations, CVs) was less than 15% and precision (expressed as the relative standard deviations, RSDs) with percentage values was less than 5.9%. Amoxicillin was found to be stable in the human plasma at room temperature (20 °C) within 8 hours. The developed method was successfully applied to the analysis of real human plasma samples. The limit of detection and limit of quantification for amoxicillin in plasma were 1.21 μg ml(-1) and 3.48 μg ml(-1), respectively.     

High-performance liquid chromatographic assay for amiloride in plasma and urine

A sensitive and simplified high-performance liquid chromatographic procedure has been developed for quantification of amiloride in rabbit plasma, as well as human plasma and urine. Following protein precipitation with perchloric acid, the supernatant was directly injected into a C18 Nucleosil column. The mobile phase consisted of methanol-water (45:55) containing 0.1 M perchloric acid, and the compound was quantitated using a fluorescence detector at excitation and emission wavelengths of 286 and 418 nm, respectively. The average recovery was 97.6%. The calibration curve was linear over the range 2.0-20.0 ng/ml. The limit of detection was 0.5 ng/ml.     

High-performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection.

A sensitive and precise high-performance liquid chromatographic procedure has been developed for the measurement of tiagabine concentrations in human plasma. Isolation of tiagabine and the internal standard was achieved using solid-phase extraction on disposable C8 columns. Separation was performed on a C18 analytical column using a mobile phase containing sodium octanesulfonate. The effluent was monitored with coulometric electrochemical detection at ca. + 0.76 V. The workup procedure recovered more than 95% of tiagabine from plasma. Standard curves were linear over the concentration range 0-500 ng/ml. The precision of the method was good: coefficients of variation were typically less than 5% for concentrations as low as 8 ng/ml and although they were higher at concentrations less than 8 ng/ml, they remained within acceptable limits (less than 17%) for concentrations as low as the limit of quantitation (2 ng/ml using a l-ml plasma sample). The stability of tiagabine in plasma was excellent, with no evidence of degradation after 23 h at room temperature or 2 months at -20 degrees C.     

Quantitative analysis of 6,11-dihydro-11-oxo-dibenz[b,e] oxepin-2-acetic acid (isoxepac) in plasma and urine by gas--liquid chromatography

A method is described for the quantitative analysis of 6,11-dihydro-11-oxo-dibenz[b,e]-oxepin-2-acetic acid (isoxepac) in plasma and urine. Isoxepac and internal standard was analysed by gas-liquid chromatography using a flame ionization detector. The method is accurate and precise over the range 0.1--30 microgram/ml. The method has been applied to the analysis of plasma and urine from both healthy volunteers and patients receiving therapeutic oral doses of isoxepac.     

A very precise high-performance liquid chromatographic procedure for the determination of cefmenoxime, a new cephalosporin antibiotic, in plasma

A simple and very precise high-performance liquid chromatographic procedure has been developed for the determination of cefmenoxime, a new broad spectrum cephalosporin antibiotic, in plasma. The workup procedure involves ultrafiltration of samples which have been treated with sodium dodecyl sulfate to displace the drug from its binding sites on plasma proteins. The ultrafiltrates are then directly injected into a high-performance liquid chromatographic system utilizing a reversed-phase analytical column, and an ultraviolet spectrophotometric detector. The mean assay coefficient of variation over a concentration range of 0.5-200 micrograms/ml is slightly greater than 1% when either p-nitrobenzoic or p-anisic acid is used as the internal standard. Recoveries of drug are essentially quantitative at all levels investigated; hence the calibration curves are rectilinear from the limit of quantification (about 0.05 microgram/ml) to at least 200 micrograms/ml.     

High-performance liquid chromatographic method for the determination of a potential memory-enhancing compound (CL 275,838) and its desbenzyl metabolite in rat plasma or serum.

A rapid, selective, precise reversed-phase liquid chromatographic method has been developed for the determination of a potential memory-enhancing agent (CL 275,838) and its main metabolite (CL 286,527) in plasma and serum. The procedure includes isolation of compounds from proteins precipitated with acetonitrile, subsequent resolution by reversed-phase (Whatman Partisphere C8) high-performance liquid chromatography and ultraviolet detection. The assay was linear over the range 0.12-1.25 micrograms/ml of plasma or serum. The detection limit was 0.12 micrograms/ml, using 0.2 ml of plasma or serum. Intra- and inter-day validation studies indicated an acceptable precision and reproducibility of the method within the concentration range investigated, the overall coefficient of variation being less than 10%. The method is currently applied in support of pharmacological and toxicity studies of the compound in rodents.     

Quantitative Determination of Acenocoumarin in Anticoagulated Patients

Abstract

A new procedure of pre-concentration on Tenax GC followed by high performance liquid chromatography analysis has been developed for the quantitative determination of acenocoumarin in human plasma. The recovery of acenocoumarin was greater than 90% over a concentration range of 0.10 to 1.00 μg/ml and the limit of quantitation by the assay was 10 ng/ml of plasma. This method allows quantitative determinations in patients under acenocoumarin therapy and can be used as a routine clinical monitoring.